



PHARMACEUTICAL 2019

Sage Therapeutics Inc. Rank 152 of 371











The relative strengths and weaknesses of Sage Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sage Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 209% points. The greatest weakness of Sage Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 60% points.

The company's Economic Capital Ratio, given in the ranking table, is -109%, being 223% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	944,695
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	86,030
Liabilities, Non-Current	3,704
Other Assets	2,367
Other Compr. Net Income	-486
Other Expenses	0
Other Liabilities	0
Other Net Income	20,356
Property and Equipment	5,643
Research and Development	282,107
Revenues	90,273
Selling, General and Administrative Expense	201,404

Output Variable	Value in 1000 USD
Assets	952,705
Liabilities	89,734
Expenses	483,511
Stockholders Equity	862,971
Net Income	-372,882
Comprehensive Net Income	-373,125
Economic Capital Ratio	-109%

